Related Experiment Video

Updated: Dec 8, 2025

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

1.3K

Dyslipidemia in patients with chronic kidney disease: etiology and management

Magdaléna Dušejovská, Marek Vecka, Ivan Rychlík

    Vnitrni Lekarstvi
    |September 18, 2020
    PubMed

    Insights

    Chronic kidney disease (CKD) affects 10-13% globally, with cardiovascular disease (CVD) being a major cause of death in dialysis patients. Research aims to find markers for lipid disorders to reduce CVD risk and improve patient quality of life.

    Area of Science:

    • Nephrology
    • Cardiology
    • Metabolic Disorders

    Background:

    • Chronic kidney disease (CKD) affects 10-13% of the global population.
    • Cardiovascular disease (CVD) is a leading cause of mortality in CKD patients, particularly those on dialysis.
    • In 2016, the Czech Republic had 6,739 patients on regular dialysis, with 43% of deaths attributed to cardiovascular complications.

    Purpose of the Study:

    • To identify a common predictive marker for lipid metabolism disorders in dialysis patients.
    • To stratify patients for potential hypolipidemic therapy.
    • To minimize cardiovascular risk and improve the quality of life for patients undergoing regular dialysis.

    Main Methods:

    • Expert group review of lipid metabolism disorders in CKD patients.
    • Focus on identifying predictive markers for cardiovascular risk stratification.
    • Exploration of potential therapeutic targets for hypolipidemic therapy.

    Main Results:

    • High mortality from cardiovascular complications in dialysis patients (43% in 2016).
    • Need for better predictive markers for cardiovascular risk in CKD.
    • Potential for therapeutic interventions targeting lipid metabolism.

    Conclusions:

    • Effective management of lipid disorders is crucial for reducing cardiovascular mortality in dialysis patients.
    • Identifying reliable biomarkers can aid in patient stratification and personalized treatment.
    • Reducing cardiovascular risk is key to improving long-term outcomes and quality of life for CKD patients.

    Keywords:
    chronic kidney diseasedyslipidemiahypolipidemic therapyregular dialysis treatment

    More Related Videos

    Assessment of Vascular Function in Patients With Chronic Kidney Disease08:50

    Assessment of Vascular Function in Patients With Chronic Kidney Disease

    Published on: June 16, 2014

    16.6K
    Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles09:15

    Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

    Published on: November 10, 2017

    14.9K

    Related Concept Videos

    Chronic Kidney Disease II: Clinical Manifestations01:24

    Chronic Kidney Disease II: Clinical Manifestations

    Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
    403
    Chronic Kidney Disease III: Interprofessional Care01:28

    Chronic Kidney Disease III: Interprofessional Care

    Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
    243
    Chronic Kidney Disease IV: Nursing Management01:18

    Chronic Kidney Disease IV: Nursing Management

    Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
    191
    Chronic Kidney Disease I: Introduction01:25

    Chronic Kidney Disease I: Introduction

    Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
    398
    Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

    Lipid-Lowering Drugs: Statins and Miscellaneous Agents

    Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
    1.2K
    Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

    Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

    In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
    109